Gossamer Bio Q4 2024 net loss $33M; PROSERA Phase 3 topline due Q4 2025

Gossamer Bio, Inc.

Cash, equivalents and marketable securities $294.5M at year-end; runway into H1 2027.
Full-year 2024 net loss $56.5M ($0.25/share) vs $179.8M ($1.18) in 2023.
R&D expenses $138.5M in 2024 vs $135.3M in 2023; G&A $36.1M vs $38.5M.
PROSERA Phase 3 in PAH on track for topline data readout in Q4 2025.
PH-ILD registrational Phase 3 to commence H2 2025; seralutinib got Japan orphan PAH designation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.